ArticleThoracic cancer2026
Danshensu Ethyl Ester Induces Ferroptosis Through Targeted Inhibition of SLC7A11 Transport Function in NSCLC.
Article in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundFerroptosis is a novel research avenue for cancer therapy. The roles of Danshensu derivatives remain unclear. This study investigated the effect of Danshensu Ethyl Ester (DEE) on ferroptosis in non-small cell lung cancer (NSCLC) cells.
methodsNSCLC cells were treated with DEE to assess ferroptosis markers, including reactive oxygen species (ROS), malondialdehyde (MDA), glutathione (GSH), and mitochondrial membrane potential (MMP), along with related protein expression. Molecular docking and dynamics simulations predicted the DEE-SLC7A11 interaction. Intracellular cysteine levels were quantified by ELISA. The functional involvement of SLC7A11 was further verified through its knockdown and overexpression. The in vivo antitumor activity of DEE was assessed using a nude mouse xenograft model.
resultsDEE treatment dose-dependently promoted cell death in A549 and H1299 cells, accompanied by increased levels of ROS and MDA, reduced GSH and MMP, and downregulated expression of SLC7A11 and GPX4. These effects were reversed by ferroptosis inhibitor Ferrostatin-1 (Fer-1), confirming ferroptosis involvement. Mechanistically, DEE directly inhibited the transport function of SLC7A11 in a p53-independent manner and also decreased p53 protein levels in wild-type A549 cells. Consistently, DEE reduced intracellular cysteine content. Genetic silencing of SLC7A11 enhanced DEE-induced ferroptosis, whereas its overexpression attenuated the effect. In vivo, DEE significantly suppressed tumor growth in a xenograft model, exhibiting efficacy comparable to that of paclitaxel.
conclusionsDEE inhibits NSCLC progression by inducing ferroptosis through the targeted inhibition of SLC7A11 transport function via a p53-independent pathway, highlighting its potential as a novel therapeutic agent for NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.